Abstract
Low levels of zinc in serum and high in blood clots were found in 12 patients with Down's syndrome (DS). They also had an immune deficiency characterized by depressed neutrophil chemotaxis, skin hypersensitivity and lymphocyte responsiveness to PHA in vitro. The patients received zinc sulphate, corresponding to 135 mg Zn++ daily. After treatment for 2 months' serum zinc levels had increased, neutrophil chemotactic responsiveness was normal in 11 of the 12 patients and there were improved lymphocyte responses to high doses of PHA in vitro. Delayed skin reactivity to DNCB was also improved in 10 of 11 patients after zinc therapy. Zinc deficiency may in part explain the increased susceptibility to infection in DS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
